| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Biomarin Pharmaceutical Inc.'s insiders have reduced their positions by a net 17,557 shares worth roughly $1.2M.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 214.6K | $11.95M | - | |
| CFO | 123.3K | $6.86M | - | |
| VP | 84.1K | $4.68M | - | |
| VP | 61.0K | $3.40M | - | |
| Dir | 49.4K | $2.75M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 16, 2018 | George Eric Davis65 | EVP, General Counsel | Sell | 3,818 | $83.88 | $320,253.84 | -3.9% | |
| Mar 16, 2018 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 15,000 | $83.26 | $1,248,853.50 | -4.8% | |
| Mar 15, 2018 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 15,000 | $84.73 | $1,270,900.50 | -5.4% | |
| Mar 9, 2018 | Jeffrey Robert Ajer58 | EVP, Chief Commercial Officer | Sell | 2,972 | $82.39 | $244,863.08 | -5.1% | |
| Mar 5, 2018 | George Eric Davis65 | EVP, General Counsel | Sell | 2,105 | $79.04 | $166,379.20 | -2.3% | |
| Feb 15, 2018 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 10,000 | $84.63 | $846,285.00 | -4.2% | |
| Feb 1, 2018 | George Eric Davis65 | EVP, General Counsel | Sale+OE | 30,000 | $90.66 | $2,719,665.00 | -26.6% | |
| Jan 5, 2018 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 10,000 | $90.32 | $903,203.00 | -4.2% | |
| Jan 2, 2018 | V Bryan Lawlis53 | Director | Sale+OE | 3,750 | $88.84 | $333,150.00 | -20.2% | |
| Jan 2, 2018 | Henry J Fuchs | President, Worldwide R& D | Sale+OE | 15,000 | $89.23 | $1,338,400.50 | -10.1% |